Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively participating in the upcoming BIO-Europe® conference, highlighting its focus on biopharmaceutical development and its pipeline of products aimed at addressing various health challenges [1][3]. Company Overview - Tonix Pharmaceuticals is a fully integrated biopharmaceutical company with marketed products and a robust pipeline [3]. - The company specializes in therapies for pain management and public health challenges, particularly focusing on central nervous system (CNS) disorders [3]. - Tonix's commercial subsidiary, Tonix Medicines, markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment [3]. Product Development - The company is advancing TNX-102 SL, a candidate for fibromyalgia management, for which an NDA has been submitted based on two significant Phase 3 studies [3]. - TNX-102 SL has received Fast Track designation from the FDA for fibromyalgia treatment and is also being developed for acute stress reaction and disorder [3]. - Other notable products in development include TNX-1300 for cocaine intoxication, which has FDA Breakthrough Therapy designation, and TNX-1500 for organ transplant rejection and autoimmune diseases [3]. - Tonix is also developing TNX-2900 for Prader-Willi syndrome and a vaccine for mpox, TNX-801 [3]. - The company has secured a contract with the U.S. Department of Defense for up to $34 million over five years to develop TNX-4200, targeting broad-spectrum antiviral agents [3]. Conference Participation - Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, will present at the BIO-Europe® conference on November 4, 2024, at 1:00 p.m. CET [1].